Tesamorelin vs Triptorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Tesamorelin
Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat.
Full profileTriptorelin
Potent synthetic GnRH agonist approximately 100× more potent than native GnRH. Used clinically for prostate cancer, endometriosis, and precocious puberty via sustained suppression. A single low dose (100mcg IM) is studied as a 'PCT restart' strategy that exploits the initial LH/FSH flare before receptor desensitization sets in.
Full profile| Tesamorelin | Triptorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | Egrifta, Egrifta SV, TH9507, GHRH analog | GnRH agonist, Decapeptyl, Trelstar, D-Trp6-LHRH |
| Evidence | FDA-approved | Research-stage |
| Dosing range | 1.28mg–2mg mg, once daily (subcutaneous) | 50mcg–200mcg mcg, Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical) |
| Administration | Subcutaneous injection (abdomen, with site rotation) | Intramuscular injection, Subcutaneous injection |
| Key side effects | Injection site reactions (erythema, pruritus), Peripheral edema, Arthralgia (joint pain), Myalgia | Initial testosterone surge followed by suppression (with repeated dosing), Hot flashes, Decreased libido, Bone density loss (long-term repeated dosing) |
| Cited sources | 5 references | 2 references |
Key differences
- Evidence level differs: Tesamorelin is fda-approved, while Triptorelin is research-stage.
- Administration: Tesamorelin — Subcutaneous injection (abdomen, with site rotation); Triptorelin — Intramuscular injection, Subcutaneous injection.
- Dosing units differ: Tesamorelin is dosed in mg, Triptorelin in mcg — they operate at different scales.
- Frequency: Tesamorelin is typically once daily (subcutaneous); Triptorelin is Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical).
- Research depth: this profile cites 5 sources for Tesamorelin vs 2 for Triptorelin.
How each works
Tesamorelin
Tesamorelin stimulates pulsatile growth hormone (GH) release from the pituitary, raising serum IGF-1 and preferentially reducing visceral adipose tissue (VAT). FDA-registration trials (Falutz et al., NEJM 2007; JAIDS 2010) showed ~15% VAT reduction versus placebo over 26 weeks. Later randomized trials (Stanley et al., JAMA 2014; Lancet HIV 2019) extended the evidence to liver fat, showing meaningful reductions in hepatic fat fraction and attenuated fibrosis progression in HIV-associated NAFLD.
Triptorelin
Triptorelin produces a biphasic response: an initial agonist surge of LH and FSH (the 'flare effect') followed by complete pituitary desensitization with continued use. The single-dose PCT protocol leverages only the initial flare to jumpstart testosterone production. Clinical data supports LH surges of 10–20× baseline within hours of the first dose.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.